Goserelin Dosing and Cost
Goserelin is available in two depot formulations: 3.6 mg administered subcutaneously every 4 weeks or 10.8 mg administered subcutaneously every 12 weeks, with 6-month costs ranging from approximately $3,026 (Medicare pricing) to substantially lower with 340B pricing at $109-$504 per dose depending on formulation. 1
Dosing Regimens
Standard Dosing Options
- Monthly formulation: 3.6 mg subcutaneous depot every 4 weeks 1, 2, 3
- 3-month formulation: 10.8 mg subcutaneous depot every 12 weeks 1, 2, 3
Both formulations achieve equivalent ovarian suppression and testosterone suppression in their respective indications. The 10.8 mg formulation has demonstrated non-inferiority to monthly 3.6 mg dosing in multiple studies 4, 5, with the advantage of less frequent administration while maintaining therapeutic efficacy.
Clinical Context for Dosing
- Prostate cancer: Either formulation achieves castrate testosterone levels (testosterone suppressed to surgically castrated range) 3
- Breast cancer (ovarian suppression): Both formulations effectively suppress ovarian function when combined with tamoxifen or aromatase inhibitors 2, 6
- Endometriosis/gynecologic conditions: 3.6 mg monthly is the typical regimen 7
The 3-month depot offers improved convenience with only 4 injections per year versus 13 with monthly dosing, without compromising efficacy 4, 5.
Cost Analysis
6-Month Treatment Costs 1
Goserelin 3.6 mg (monthly):
- Medicare: $3,025.80
- 340B pricing: $504.30 per dose
Goserelin 10.8 mg (every 12 weeks):
- Medicare: $3,025.80 (for 6 months, 2 doses)
- 340B pricing: $108.85 per dose
Cost-Effectiveness Considerations
The 340B pricing represents a dramatic cost reduction compared to Medicare pricing, making goserelin accessible for eligible institutions treating underserved populations. When comparing formulations at equivalent pricing tiers, the 10.8 mg formulation provides the same 6-month cost but with fewer injections and clinic visits 1.
For prostate cancer specifically, long-term adjuvant goserelin combined with radiotherapy has demonstrated cost-effectiveness at approximately $16,500 CAD ($11,000 USD) per life-year gained 8, well below the $50,000 per life-year threshold for cost-effectiveness.
Important Cost Caveats
- Group Purchasing Organization (GPO) pricing may offer intermediate rates between 340B and Medicare
- Actual patient out-of-pocket costs depend on insurance coverage, deductibles, and coinsurance
- The 3-month formulation reduces indirect costs (fewer clinic visits, less time off work) though this isn't captured in drug acquisition costs alone 1
Practical Prescribing Points
Formulation selection: Choose the 10.8 mg 3-month depot when possible for patient convenience and equivalent efficacy 4, 5. The monthly 3.6 mg remains appropriate when shorter treatment intervals are preferred or for specific protocols requiring monthly dosing.
Administration: Both are subcutaneous depot injections, typically administered in the anterior abdominal wall 3.